Cite
Tarantelli C, Bernasconi E, Gaudio E, et al. BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance. ESMO Open. 2018;3(6):e000387doi: 10.1136/esmoopen-2018-000387.
Tarantelli, C., Bernasconi, E., Gaudio, E., Cascione, L., Restelli, V., Arribas, A. J., Spriano, F., Rinaldi, A., Mensah, A. A., Kwee, I., Ponzoni, M., Zucca, E., Carrassa, L., Riveiro, M. E., Rezai, K., Stathis, A., Cvitkovic, E., & Bertoni, F. (2018). BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance. ESMO open, 3(6), e000387. https://doi.org/10.1136/esmoopen-2018-000387
Tarantelli, Chiara, et al. "BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance." ESMO open vol. 3,6 (2018): e000387. doi: https://doi.org/10.1136/esmoopen-2018-000387
Tarantelli C, Bernasconi E, Gaudio E, Cascione L, Restelli V, Arribas AJ, Spriano F, Rinaldi A, Mensah AA, Kwee I, Ponzoni M, Zucca E, Carrassa L, Riveiro ME, Rezai K, Stathis A, Cvitkovic E, Bertoni F. BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance. ESMO Open. 2018 Sep 26;3(6):e000387. doi: 10.1136/esmoopen-2018-000387. eCollection 2018. PMID: 30305939; PMCID: PMC6173228.
Copy
Download .nbib